Press Releases Archives

insitro and Bristol Myers Squibb Collaboration Expanded with Nomination of New Targets

Collaboration expands to include two additional therapeutic targets for the treatment of ALS discovered via insitro’s AI-driven Virtual Human™platform Joint effort focuses on identifying key biological drivers to deliver disease-modifying…

insitro Appoints Joe Hand as Chief People Officer to Advance Talent Strategy for Next Stage of Development

Seasoned life sciences executive brings deep expertise in scaling organizations and enterprise leadership through transformative growth SOUTH SAN FRANCISCO, Calif. – Feb 26, 2026 – insitro, the AI therapeutics company…

insitro Completes First AI-Enabled Human Genetics Study of Brown Adipose Tissue, Shares Differentiated Targets with Anti-Obesity Effects

AI-enabled brown adipose tissue (BAT) phenotype unlocks population-scale human genetic discovery BAT-01 knockdown drives 15% body-weight reduction in preclinical models through peripheral adipose beiging, preserving lean mass Key findings presented…

insitro to Acquire CombinAbleAI to Complete its Full Stack, Modality-Agnostic AI Platform for Drug Discovery and Design

TherML™ integrates CombinAbleAI’s advanced, next generation biologics expertise with insitro’s existing small molecule and oligonucleotide capabilities, unifying therapeutic design across all major drug modalities in a single AI engine SOUTH…

insitro Validates AI-Enabled POSH Platform in Nature Communications, Bridging Critical Gap in Drug Discovery

New publication demonstrates that insitro’s POSH platform — integrating pooled CRISPR screening and self-supervised deep learning — successfully breaks the historic compromise between scale and depth to more rapidly identify…

insitro Appoints R&D Veteran Stephen Hitchcock and AI Visionary Vijay Pande as Scientific Advisors

Former Takeda CSO and a16z Bio + Health Founder to Guide Clinical Translationand Scaling of insitro’s ChemML™ Platform SOUTH SAN FRANCISCO, Calif. –– DEC. 3, 2025 – insitro, the AI…

insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform

Novel ALS target identified preclinically; next phase of collaboration will leverage insitro’s ChemML™ platform to discover molecules with potential as next-generation therapies for ALS insitro’s ChemML™ platform integrates proprietary binding…

insitro partners with Lilly to build first-in-kind machine learning models to advance small molecule drug discovery

SOUTH SAN FRANCISCO, Calif. – SEPTEMBER 9, 2025 – insitro, a pioneer in machine learning for drug discovery and development, today announced a new collaboration with Eli Lilly and Company…

insitro and UK’s INSIGHT at Moorfields Eye Hospital Announce Collaboration to Expand Research Efforts in Neurodegeneration and Related Conditions

The world’s largest bioresource of eye images offers window into human health and serves as basis of a new AI foundation model to boost drug discovery. SOUTH SAN FRANCISCO–insitro, a…

insitro Receives $25 Million in Milestone Payments from Bristol Myers Squibb for the Achievement of Discovery Milestones and the Selection of First Novel Genetic Target for ALS

Distinctive machine learning platform combines proprietary disease models and screening techniques to reveal genetic insights that generate targets to transform ALS treatment SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–insitro, a machine learning-enabled…